ARISTADA patients experienced an improvement in clinical condition
- The Clinical Global Impression-Improvement (CGI-I) scale allows the clinician to assess and rate improvement in mental illness on a scale of 1 (very much improved) to 7 (very much worse) based on the change in clinical condition from baseline2
- In an exploratory analysis,* improvement in CGI-I was seen for both ARISTADA® (aripiprazole lauroxil) groups vs the placebo group at each post-baseline visit1
*Exploratory analysis: Analysis of all exploratory endpoints was supportive of the prespecified key primary and secondary endpoints. However, these analyses do not allow definitive efficacy conclusions regarding treatment effects of ARISTADA to be drawn.
References: 1. Data on file. Alkermes, Inc. 2. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc; 2018.